AdjuTec Pharma AS

AdjuTec Pharma Appoints Jethro Holter as CEO to Secure Commercialisation of APC148

Oslo, Norway, 21 January 2025 – AdjuTec Pharma AS, a privately held company developing antibiotic resistance breakers, today announces the appointment of Jethro Holter as CEO of AdjuTec Pharma. He comes from a CEO position in ArcticZymes Technologies ASA and is CoB at Genetic Analysis AS.

Jethro has over two decades of international experience in the Life sciences industry. Under his leadership, he has previously commercialised innovative solutions and achieved international commercial success in the life sciences sector.

Adjutec´s lead compound APC148 is in phase 1 clinical development and will through1H2025 secure funding to support the remaining phase 1+2 program. At this stage a licence agreement will be signed to progress development of the product through late-stage clinical development and distribution to global markets. To pursue our commercial strategy, Adjutec is strengthening the team with Jethro who has an extensive experience in the life science sector including and bringing an investor network and partnering expertise to Adjutec.

Former CEO, Bjørn Klem, will continue as COO in the company to strengthen R&D activities and secure the next commercial milestones.

“We are excited to get Jethro Holter on board as CEO in Adjutec. He will strengthen the team with strategic and commercial experience, as well as investor relations through his former CEO position in a listed company. The Adjutec board is very optimistic about completing our first clinical study successfully 1st quarter 2025 that will support the next capital raise by Summer 2025 to fund our next clinical studies,” said Øyvind Kongstun Arnesen, Chair of Board.
“I am delighted to be appointed CEO. AdjuTec is one of Norway´s most promising pharma companies. The company´s groundbreaking innovations have substantial potential to address pressing and unmet health needs to combat antimicrobial resistance on a global scale. With an exceptional team supporting me, I am confident in our ability to successfully commercialise AdjuTec´s first compound, APC148,” said Jethro Holter, CEO.

About antimicrobial resistance (AMR) – https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance

AMR is a global health threat with 5 million associated deaths annually and an accumulated number of 39 mill deaths by 2050. WHO has declared that AMR is one of the top 10 global public health threats facing humanity. Misuse of antimicrobials is the main driver in the development of drug-resistant pathogens. AMR results in prolonged hospital stays at intensive care units with increased costs to the healthcare system. Without effective antimicrobial agents, the success of modern medicine in treating and preventing infections during major surgery and cancer chemotherapy, can be jeopardized.

About AdjuTec Pharma

AdjuTec Pharma is a company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market. The company technology offers a unique mechanism of action that inactivates bacterial defense enzymes and restores bacterial sensitivity to antibiotics. The company’s lead product is APC148, a selective zinc chelator targeting bacterial metallo-ß-lactamase (MBL) enzymes. The technology was invented by Professor Pål Rongved and his group at the Department of Pharmacy, University of Oslo. The company is located at Rebel, Universitetsgata 2 - downtown Oslo.

For more information, please visit www.adjutecpharma.com

Please contact: info@adjutecpharma.com

Follow us on LinkedIn and Twitter
2025-01-20 21:05